# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K112586   
B. Purpose for Submission: To obtain a substantial equivalent determination for the Ceftaroline $3 0 \mu \mathrm { g }$ , BBL SensiDisc™ Antimicrobial Susceptibility Test Disks.   
C. Measurand: Ceftaroline $3 0 \mu \mathrm { g }$   
D. Type of Test: Semi-quantitative Antimicrobial Susceptibility Test Disc   
E. Applicant: Becton Dickinson and Company   
F. Proprietary and Established Names: Ceftaroline $3 0 \mu \mathrm { g }$ BBL™ Sensi -Disc™ Antimicrobial Susceptibility Test Disks   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JTN</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>866.1620</td><td rowspan=1 colspan=1>83 Microbiology</td></tr></table>

# H. Intended Use:

1. Intended use(s):

Antimicrobial Susceptibility Test Disks are used for semi-quantitative in vitro susceptibility testing by standardized agar diffusion test procedures. Ceftaroline $3 0 \mu \mathrm { g }$ BBL™ Sensi-Disc™ is intended for use in determining the susceptibility to Ceftaroline of a wide range of bacterial pathogens.

2. Indications for use:

Use of Ceftaroline $3 0 \mu \mathrm { g } \mathrm { B B L ^ { T M } }$ Sensi-Disc™ for in vitro agar diffusion susceptibility testing is indicated when there is a need to determine the susceptibility of bacteria to Ceftaroline. The concentration of $3 0 \mu \mathrm { g }$ has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA approved drug insert for this antimicrobial agent

<table><tr><td rowspan=1 colspan=2>Active In Vitro and in Clinical Infections Against:</td></tr><tr><td rowspan=1 colspan=1>Gram-positive MicroorganismsStaphylococcus aureus(including methicillin-susceptible and -resistantisolates)Streptococcus pyogenesStreptococcus agalactiaeStreptococcus pneumoniae</td><td rowspan=1 colspan=1>Gram-negativeMicroorganismsEscherichia coliKlebsiella pneumoniaeKlebsiella oxytocaHaemophilus influenzae</td></tr><tr><td rowspan=1 colspan=2>Active In Vitro Against:</td></tr><tr><td rowspan=1 colspan=1>Gram-positive MicroorganismsStreptococcus dysgalactiae</td><td rowspan=1 colspan=1>Gram-negativeMicroorganismsCitrobacter koseriCitrobacter freundiiEnterobacter cloacaeEnterobacter aerogenesMoraxella catarrhalisMorganella morganiiProteus mirabilisHaemophilus parainfluenzae</td></tr></table>

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: None

# I. Device Description:

Ceftaroline $3 0 \mu \mathrm { g }$ BBL™ Sensi-Disc™ is prepared by impregnating high quality paper with accurately determined amounts of Ceftaroline supplied by the drug manufacturer. Each Ceftaroline disk is clearly marked on both sides with the agent and drug content. Ceftaroline cartridges each contain 50 impregnated disks that are packed as either a single cartridge in a single box, or in a package containing ten cartridges. Ceftaroline disks are used for semi-quantitative in vitro susceptibility evaluations by the agar diffusion test method.

Agar diffusion susceptibility methods employing dried filter paper disks impregnated with specific concentrations of antimicrobial agents were developed Mueller Hinton Agar was selected as the test medium and a standardized procedure was developed

# J. Substantial Equivalence Information:

1. Predicate device name(s): Ciprofloxacin $5 \mu \mathrm { g }$ , BBL™ Sensi-Disc ™ Antimicrobial Susceptibility Test Disk.

2. Predicate 510(k) number: K874425

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>An in vitro diagnostic product forclinical susceptibility testing of aerobicgram positive and gram negativebacteria</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Inoculum</td><td rowspan=1 colspan=1>Prepared from pure isolated coloniesusing the direct inoculation method orgrowth method</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Inoculation method</td><td rowspan=1 colspan=1>Directly equated to a 0.5 McFarlandturbidity standard</td><td rowspan=1 colspan=1>same</td></tr></table>

Difference   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Antibiotic</td><td rowspan=1 colspan=1>Ceftaroline</td><td rowspan=1 colspan=1>Ciprofloxacin</td></tr><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>30μg</td><td rowspan=1 colspan=1>5μg</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI M02-A10 January 2009 "Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. “CLSI M100, "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard". The Center for Drug Evaluation and Review (CDER) pharmaceutical approved package insert, developed during clinical trial studies, was used for Interpretive Criteria and Quality Control (QC) Expected Ranges.

# L. Test Principle:

Disks containing a wide variety of antimicrobial agents are applied to the surface of Mueller Hinton Agar plates [or Haemophilus Test Medium Agar for Haemophilus influenzae or Mueller Hinton Agar with $5 \%$ Sheep Blood for Streptococcus species] inoculated with pure cultures of clinical isolates (Bauer-Kirby method). Following incubation, the plates are examined and the zones of inhibition surrounding the disks are measured and compared with established zone size ranges for individual antimicrobial agents in order to determine the agent(s) most suitable for use in antimicrobial therapy. The categorical interpretation [susceptible (S), intermediate (I), or resistant (R)] for the organism being tested with the antimicrobial agent is made by comparing zone diameters to those found in the respective organism tables of FDA drug insert and/or CLSI/NCCLS Document M2 ("Performance Standards for Antimicrobial Disk Susceptibility Tests”) and of CLSI/NCCLS Document M100 ("Performance Standards for Antimicrobial Susceptibility Testing").

# M. Performance Characteristics (if/when applicable):

Descriptive characteristics are sufficient for susceptibility test discs, because the drug manufacturer performed several clinical outcome studies enrolling 1300 patients, which were evaluated by FDA Center for Drug Evaluation and Research in order to grant approval of the drug Ceftaroline. These studies generated the Interpretive Criteria and Quality Control Expected Ranges which the antimicrobial susceptibility tests disk manufactures use for interpretation of results also. No additional in vitro diagnostic clinical studies are therefore required.

1. Analytical performance:

a. Precision/Reproducibility: Not applicable   
b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods):

<table><tr><td colspan="9">Zone Diameter Interpretive Chart Quality Control Organisms</td></tr><tr><td>Antimicrobial Agent</td><td>Disc Code</td><td>Disc Potency</td><td>R</td><td>I</td><td>S</td><td>E.coli ATCCTM 25922</td><td>S. aureus ATCC 25923</td><td>P.aeruginosa ATCC 27853</td></tr><tr><td>Ceftaroline Staphylococcus aureus (including methicillin- resistant isolates skin isolates only)</td><td>CPT- 30</td><td>30 μg</td><td></td><td></td><td>≥24</td><td>26-34</td><td>26-35</td></tr><tr><td>Streptococcus agalactiae (skin isolates only) Streptococcus pyogenes (skin isolates only)</td><td></td><td></td><td></td><td></td><td>≥ 26 ≥24</td><td>S. pneumoniae ATCC 49619</td><td></td></tr><tr><td>Streptococcus pneumoniae (CABP isolates only)</td><td></td><td></td><td></td><td>—</td><td>≥27</td><td>31-41</td><td></td></tr><tr><td>Haemophilus influenzae (CABP isolates only)</td><td></td><td></td><td></td><td></td><td>≥ 33</td><td>H. influenzae ATCC 49247 29-39</td><td></td></tr></table>

d. Detection limit: Not applicable e. Analytical specificity: Not applicable

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Not applicable

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

Staphylococcus aureus $\geq 2 4 \mathrm { m m } \left( \mathrm { S } \right) ^ { \ast }$   
Streptococcus agalactiae $\mathrm { \dot { \geq } 2 6 m m \left( S \right) ^ { \ast } }$   
Streptococcus pyogenes ≥ 24mm (S)\*   
Streptococcus pneumoniae $\geq 2 7 \mathrm { m m } \left( \mathrm { S } \right) ^ { * }$   
Haemophilus influenzae $\geq 3 3 \mathrm { m m } \left( \mathrm { S } \right) ^ { * }$   
Enterobacteriaceae $\geq 2 3 ~ \mathrm { m m }$ (S) $2 0 { - } 2 2 \ \mathrm { m m } \left( \mathrm { ~ I ~ } \right) \leq 1 9 \ \mathrm { m m } \left( \mathrm { R } \right)$ )

$\mathrm { S } =$ susceptible, $\mathrm { I } =$ intermediate, $\mathrm { R } =$ resistant \* The current absence of resistant isolates precludes defining any results other than “Susceptible”. Isolates yielding MIC or disk diffusion results suggestive of “Nonsusceptible” should be subjected to additional testing.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809. 10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.